Zhengwu Sun (Former)
1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
-
Mark
Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation
(
- Contribution to journal › Article
- 2006
-
Mark
Pancreatitis-associated pulmonary injury - effects of Lexipafant, a PAF-antagonist
(
- Contribution to journal › Article
- 2005
-
Mark
Severity of pancreatitis-associated gut barrier dysfunction is reduced following treatment with the PAF inhibitor lexipafant.
(
- Contribution to journal › Article
- 2002
-
Mark
Early treatment with lexipafant, a platelet-activating factor-receptor antagonist, is not sufficient to prevent pulmonary endothelial damage after intestinal ischaemia and reperfusion in rats.
(
- Contribution to journal › Article
-
Mark
Experimental pancreatitis causes acute perturbation of energy metabolism in the intestinal wall
(
- Contribution to journal › Article
-
Mark
Gut barrier permeability, reticuloendothelial system function and protease inhibitor levels following intestinal ischaemia and reperfusion--effects of pretreatment with N-acetyl-L-cysteine and indomethacin.
(
- Contribution to journal › Article
-
Mark
The effect of intestinal ischemia and reperfusion injury on ICAM-1 expression, endothelial barrier function, neutrophil tissue influx, and protease inhibitor levels in rats.
(
- Contribution to journal › Article
-
Mark
NF-kappaB activation and inhibition: a review.
(
- Contribution to journal › Scientific review
-
Mark
Effective treatment of gut barrier dysfunction using an antioxidant, a PAF inhibitor, and monoclonal antibodies against the adhesion molecule PECAM-1.
(
- Contribution to journal › Article
- 2000
-
Mark
Intestinal Ischemia and Reperfusion Injury - Pathophysiology as basis for novel treatment
2000)(
- Thesis › Doctoral thesis (compilation)